Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...

Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...

Georgiamune, an immunology-focused biotech out of Maryland, has licensed a preclinical cancer drug candidate to Menarini ...

Quest Diagnostics is the latest life sciences company to fall victim to a cyberattack, with the company believing patient ...

Japan's Astellas Pharma has tapped Boston computational discovery company AI Proteins in a drug discovery deal potentially ...

Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...

Roche has dived into the data behind its filing for FDA approval of fenebrutinib in multiple sclerosis (MS), unpacking the ...

| GSK may have cemented its hepatitis B credentials with Tuesday’s landmark FDA nod for its “functional cure” bepirovirsen, ...

Medtech M&A reached its highest level in more than a decade, EY found, with a total disclosed deal value of roughly $130 ...

The FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent ...

Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...